Under pressure, Biogen outlines ambitious diversity goals for Aduhelm study — but the Medicare fight is still on
Biogen, facing renewed criticism for a lack of diversity in its Alzheimer’s clinical trials, announced on Thursday a new commitment: At least 18% of the participants in the FDA-mandated confirmatory study for its controversial drug Aduhelm will be Black or Latinx.
The promise comes after decades in which Black and Latinx Americans were chronically underrepresented in trials for the memory-wasting disease, despite being up to twice as likely to have it. And it comes just weeks after the company was specifically told by CMS to include these groups in another clinical trial before insurers pay for Aduhelm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.